title: One year clinical outcomes of renal artery stenting: the results of ODORI Registry.
abstract: The safety, efficacy and long term clinical benefits of renal artery revascularization by stenting are still a matter of debate. The aim of our study was to define the safety and efficacy of renal artery stenting with the Tsunami peripheral stent (Terumo Corporation, Tokyo, Japan). The ODORI was a prospective, multicentre registry which enrolled 251 consecutive patients, (276 renal arteries) in 36 centres across Europe. The primary endpoint was acute procedural success defined as <30% residual stenosis after stent placement. Secondary endpoints included major adverse events, blood pressure control, serum creatinine level, and target lesion revascularization (TLR) at 6 and 12 months. Patients were 70 +/- 10 years old, 59% were male, 33% had diabetes, and 96% hypertension. The main indications for renal stent implantation were hypertension in 83% and renal salvage in 39%. Direct stent implantation was performed in 76% of the cases. Acute success rate was 100% with residual stenosis of 2.5 +/- 5.4%. Systolic/diastolic blood pressure decreased from a mean of 171/89 at baseline to 142/78 mmHg at 6 months (p < 0.0001 vs. baseline), and 141/80 mmHg at 12 months (p < 0.0001 vs. baseline). Mean serum creatinine concentration did not change significantly in the total population. However, there was significant improvement in the highest tercile (from 283 micromol/l at baseline to 205 and 209 micromol/l at 6 and 12 months respectively). At 12-months, rates of restenosis and TLR were 6.6 and 0.8% respectively. The 12 month cumulative rate of all major clinical adverse events was 6.4% while the rate of device or procedure related events was 2.4%. In hypertensive patients with atherosclerotic renal artery stenosis Tsunami peripheral balloon-expandable stent provides a safe revascularization strategy, with a potential beneficial impact on hypertension control and renal function in the highest risk patients.
authors.affiliation: Hôpital Européen Georges Pompidou, Cardiovascular Radiology, 20 rue Leblanc, 75015 Paris, France. marc.sapoval2@egp.aphp.fr
authors.forename: M
authors.initials: M
authors.lastname: Sapoval
authors.forename: I
authors.initials: I
authors.lastname: Tamari
authors.forename: P
authors.initials: P
authors.lastname: Goffette
authors.forename: M
authors.initials: M
authors.lastname: Downes
authors.forename: Q
authors.initials: Q
authors.lastname: Senechal
authors.forename: F
authors.initials: F
authors.lastname: Fanelli
authors.forename: P
authors.initials: P
authors.lastname: Reimer
authors.forename: Z
authors.initials: Z
authors.lastname: Negaiwi
authors.forename: P
authors.initials: P
authors.lastname: De Cassin
authors.forename: S
authors.initials: S
authors.lastname: Heye
authors.forename: V
authors.initials: V
authors.lastname: Korobov
authors.forename: D
authors.initials: D
authors.lastname: Tsetis
authors.forename: H
authors.initials: H
authors.lastname: Abada
mesh_terms: D000368:Aged; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D007677:Kidney Function Tests; D008297:Male; D011446:Prospective Studies; D011474:Prosthesis Design; D012008:Recurrence; D012042:Registries; D012078:Renal Artery Obstruction / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome
chemical_list: D003404:Creatinine